KBC Group
PTCT icon

KBC Group’s PTC Therapeutics PTCT Stock Holding History

KBC Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Hold
2,347
– – ﹤0.01% 1063
2025
Q4 		$178K Hold
2,347
– – ﹤0.01% 965
2025
Q3 		$144K Hold
2,347
– – ﹤0.01% 1058
2025
Q2 		$115K Sell
2,347
-724
-24% -$34.4K ﹤0.01% 1115
2025
Q1 		$156K Buy
3,071
+26
+0.9% +$1.3K ﹤0.01% 1217
2024
Q4 		$137K Buy
3,045
+813
+36% +$34.8K ﹤0.01% 1350
2024
Q3 		$83K Buy
2,232
+504
+29% +$16.9K ﹤0.01% 1416
2024
Q2 		$53K Sell
1,728
-442
-20% -$14.3K ﹤0.01% 1583
2024
Q1 		$63K Buy
2,170
+619
+40% +$17.3K ﹤0.01% 1410
2023
Q4 		$43K Hold
1,551
– – ﹤0.01% 1634
2023
Q3 		$35K Buy
+1,551
New +$57.7K ﹤0.01% 1714

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KBC Group's PTCT Position: Q1 2026 in Review

KBC Group held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 2,347 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

KBC Group first reported a position in PTCT in Q3 2023 and has held it in 11 quarters since. The position peaked at $178K in Q4 2025. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • KBC Group held 2,347 shares of PTC Therapeutics worth $160K as of Q1 2026.
  • KBC Group left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1063 holding.
  • KBC Group first reported a position in PTC Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's PTC Therapeutics position peaked at $178K in Q4 2025.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.